Planar lens integrated capillary action microfluidic immunoassay device for the optical detection of troponin I by Mohammed, Mazher-Iqbal & Desmulliez, Marc P. Y.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
Planar lens integrated capillary action microfluidic immunoassay device for 
the optical detection of troponin I 
Citation:  
Mohammed, Mazher-Iqbal and Desmulliez, Marc P. Y. 2013, Planar lens integrated capillary 
action microfluidic immunoassay device for the optical detection of troponin I, 
Biomicrofluidics, vol. 7, no. 6, 064112, pp. 1-13 
DOI: http://www.dx.doi.org/10.1063/1.4837755 
 
 
 
 
© 2013, AIP Publishing 
Reproduced with permission. 
 
 
 
 
 
 
Downloaded from DRO: 
http://hdl.handle.net/10536/DRO/DU:30076580 
Planar lens integrated capillary action microfluidic
immunoassay device for the optical detection of troponin I
Mazher-Iqbal Mohammeda) and Marc P. Y. Desmulliez
Heriot-Watt University, MicroSystems Engineering Centre (MISEC), School of Engineering
& Physical Sciences, Earl Mountbatten Building, Edinburgh EH14 4AS, Scotland
(Received 9 August 2013; accepted 19 November 2013; published online 5 December 2013)
Optical based analysis in microfluidic and lab-on-a-chip systems are currently
considered the gold standard methodology for the determination of end point
reactions for various chemical and biological reaction processes. Typically, assays
are performed using bulky ancillary apparatus such as microscopes and complex
optical excitation and detection systems. Such instrumentation negates many of the
advantages offered by device miniaturisation, particularly with respect to overall
portability. In this article, we present a CO2 laser ablation technique for rapidly
prototyping on-chip planar lenses, in conjunction with capillary action based
autonomous microfluidics, to create a miniaturised and fully integrated optical
biosensing platform. The presented self-aligned on-chip optical components offer an
efficient means to direct excitation light within microfluidics and to directly couple
light from a LED source. The device has been used in conjunction with a miniaturised
and bespoke fluorescence detection platform to create a complete, palm sized system
(60  80  60 mm) capable of performing fluoro-immunoassays. The system has
been applied to the detection of cardiac Troponin I, one of the gold standard
biomarkers for the diagnosis of acute myocardial infarction, achieving a lower
detection limit of 0.08 ng/ml, which is at the threshold of clinically applicable
concentrations. The portable nature of the complete system and the biomarker
detection capabilities demonstrate the potential of the devised instrumentation for use
as a medical diagnostics device at the point of care. VC 2013 AIP Publishing LLC.
[http://dx.doi.org/10.1063/1.4837755]
I. INTRODUCTION
Lab-on-a-chip and microfluidic based systems hold considerable promise for a vast range
of chemical and biological processing applications. For such systems fluorescence based optical
analysis has become the gold standard technique by which end point reactions are determined,
typically using a laser excitation source with imaging microscopy.1,2 In such setups, optical
detection apparatus and its associated instrumentation greatly increase the overall size of the
complete system, negating the many benefits of device miniaturisation and limiting the portable
nature of such a technology. In addition laser systems are relatively expensive, can have rela-
tively high power consumption, can be bulky for variants in specific wavelengths for use with
prominent fluorophores and require safety protocols for their use within a laboratory.
Increasingly for microdevice applications, LEDs have proven to be a cost effective alternative
to laser sources as they are readily available off the shelf, produce high luminosities across a
wide range of optical wavelengths, have relatively low power consumption and are be readily
integrated into miniaturised platforms. Such sources are broadband and have large half angles
of emission, therefore requiring focusing lenses and band-pass optical filters. The resulting
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optical excitation setup can therefore be several orders of magnitude larger than the microflui-
dic chip itself and require careful manual configuration to optimise the setup.
To reduce the size of the overall system, much attention has been focused on the integra-
tion of on-chip light guiding structures. Various light delivery and focusing components ranging
from planar/3D lenses3–12 to waveguides13,14 have been demonstrated in integrated microfluidic
and lab-on-a-chip devices. The primary advantages to such on-chip integration, in addition to
the reduced size of key optical elements, are the self-alignment of the components and the abil-
ity to more tightly focus light onto microfluidic channels. However, most demonstrated formats
require the use of larger ancillary equipment, e.g., laser excitation sources, light guiding fibres,
light collimators or fluorescence microscopes, which negates many of the benefits from device
miniaturisation. Of all the demonstrated strategies, planar light guiding structures have demon-
strated a high efficiency for light focusing within microsystems, with greatly reduced overall
design complexity and modest increases in the total device footprint.3–10,12 In the work con-
ducted by Seo et al., for example, significant consideration was paid to complete device minia-
turisation, where a disposable format was created that operated directly from an LED excitation
source, with no additional devices required for light coupling.9 Additionally, it was found that
2D Polydimethylsiloxane (PDMS) based microlenses confined the excitation emission within
the chip and yielded no detectable excitation light orthogonal to the chip plane, resulting in a
7-fold increase in the detected fluorescence intensity from a sample of fluorescent nanospheres.
This work was not exploited further however in more advanced systems and currently no bio-
microfluidic system has demonstrated the advantageous use of integrated light guides by which
to perform any biological or chemical based assays.
In this article, we assess the performance of various 2D planar lenses combined with capillary
microfluidics and biosensing elements, all manufactured within PMMA substrate using CO2 laser
thermal processing. As a demonstration of the complete system, fluoro-immunoassays were per-
formed on-chip within the fabricated microfluidic channels to investigate the detection of the
cardiac biomarker Troponin I (cTnI), which is considered the gold standard clinical biomarker for
the diagnosis of acute myocardial infarction (AMI).15 The complete system of the microfluidic
channels and planar lenses are fabricated in a single process by the CO2 laser. The lenses are then
post-processed by polishing to remove imperfections. The entire chip is then thermally bonded to
seal the microfluidic channels and further remove residual defects on the lens surface. This article
presents the first demonstration of capillary microfluidic systems with integrated planar lens optics
for biosensing purposes. The integration of on-chip light guiding structures onto autonomous capil-
lary microfluidic devices unlocks the potential of such detection systems to be utilised as a com-
plete working platform for alternative reaction processes requiring fluorescence excitation and/or
detection such as DNA hybridisation assays16,17 and Bioluminescence Resonance Energy Transfer
(BRET) assays.18
II. EXPERIMENTAL
A. Materials and fabrication
Laser thermal processing is an attractive alternative to established micro manufacturing
techniques as such a technology has a rapid turnaround time and does not require fixed photo-
masks, embossing tools or clean room environment.19–26 However, the quality of manufactured
microfluidics and the surface quality of the lenses are better defined, with fewer manufacturing
defects using techniques such as photolithography.
All structures demonstrated in this work were manufactured using a class 2 CO2 laser etching
system (Epilog, UK), which allows for repeatable micro feature sizes above 150lm. The laser
system has a maximum power of 40W, maximum scan speed of 96mm/s, operates in the near
infrared region with a wavelength of 10.6lm for a spot size of 76–127lm. All PMMA substrates
were purchased precast from Weatherall Equipment & Instruments Ltd (Bucks, UK). All devices
were manufactured from CLAREX
VR
precision thin sheet PMMA, made by a specialist
cell-casting technique which ensures very high surface uniformity. Designs of the microfluidic
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systems and 2D planar lenses were carried out using Corel Draw X4 (Corel Software, USA)
interfaced directly with the CO2 laser.
The type of substrate that can be laser ablated depends highly on the material absorption
properties, the properties of the laser system (spot size, power, etc) and the fine control of the
laser/substrate translational stage. PMMA is manufactured based on its physical ability to absorb
the radiation produced by the laser, with the power required to etch a given depth depending on
the melting and vaporisation temperatures of the polymer. The scan speed and power of the laser
can be adjusted across a percentage scale from 0 to 100% of the maximum scan speed and laser
power, in 1% increments, across either high or low power modes, as described previously.19 For
the final manufacturing phase, the lenses and microfluidic channels were made in a single pass
using a laser scan speed of 50% and power of 30%, with the laser set to high power mode.
This work presents the very first instance by which microlenses have been fabricated by CO2
laser ablation, in conjunction with simple backend post processing, and embedded for use within
a microfluidic system. Additionally, we described a novel new manufacturing process by which
to create microfluidic systems using CO2 laser ablation of PMMA. All microfluidic channels and
planar lenses were fabricated by the laser thermally cutting through a given sheet of PMMA, fol-
lowed by lamination with a modified top layer, containing entry and exit ports and a blank bot-
tom PMMA layer, thereby sealing the microfluidic channel. 500lm thick PMMA sheets we used
in the fabrication process of each layer, thereby producing microfluidic channel and the planar
lens of a height dictated by this thickness. The final chip device, comprising a triple laminate
design, has a total thickness of 1.5mm and an approximate surface area of 30  30mm.
In our previous work, microfluidics were of a 2-layer design, with the channels etched into
one substrate and sealed with a secondary cover PMMA layer.19–21 Fabricating the microfluidic
channels by the new methodology fundamentally reduces defect formation on the upper and lower
surfaces of the microchannels, restricting defects to the side walls only. We have found through
the testing phase of the device that the fabrication route of etching the PMMA substrate to form
microchannels, where defects are found in the bulk of the channel, results in significant scattering
of the excitation and emitted light. Therefore, the newly presented microfluidic manufacturing pro-
cess is critical to improving the overall detection sensitivity of the fluoro-immunoassay. An added
benefit is that the capillary flow characteristics are also improved due to the fewer defects leading
to a reduced flow resistance on a migrating fluid.
Thermal bonding was utilised to create the final devices using a methodology described
previously.19,20 Briefly, the stacked laminate layers were placed between two borosilicate glass
microscope slides, which in turn were compressed between two 10mm thick steel plates. The
whole structure was placed within a programmable convection oven (Norbetherm, Germany)
and heated above the glass transition temperature of the PMMA (170 C) for approximately
40 min. The oven was then cooled to below the glass transition temperature (80–90 C) and
held at that temperature for 30 min before allowing the stack to cool to room temperature, with
the complete process requiring approximately 1.5–2 h. Due to the high surface uniformity of
the borosilicate glass and its much higher glass transition temperature relative to PMMA, use
of the slides ensures an even compressive pressure across the chip surface and that the surfaces
of the chip remain uniform during the bonding procedure, preserving the chips clarity for opti-
cal analysis.
B. Manufacturing limitations
Defects were observed on the surface of the lenses due to the nature of the ablation process
and the limitations of the stepper motor used to move the laser beam. The PMMA is effectively
vaporised or liquefied under the spot area of the laser. The pattern is formed as the vapours
drive out the molten material.22 This results in rough edges on the lenses and microchannel
walls, and microbubble formation when vapours become trapped within the molten material. As
lenses comprise circular edges, the minimum incremental movement of the translational stage
can become a major limiting factor to lens quality. The x-y translational movement of the laser
system has a minimum translation of 100 lm, which resulted in the surface of the lens being
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effectively rippled post processing as the laser beam attempted to form a curved pattern. Both
forms of defects found on the surfaces of the lens can be observed in Fig. 1(a).
The defects on the lens surface are an inevitable consequence of the laser manufacturing
process. However, such defects can be almost entirely removed using an abrasive polishing of
the PMMA surface. Initially, the lens surfaces are lightly filed to remove any loose debris and
the rippled edges resulting from the laser translation stage. Following this, the surface is
sequentially sanded with various grade wet and dry sandpaper, comprising 240, 600, 1200,
2400, and 4000 grit, to remove larger scratches and to improve surface clarity. Finally, the sur-
face clarity is improved further and minor scratches removed using two acrylic polishing com-
pounds (Glass Polish LTD, UK). Post polishing, as the PMMA is heated during bonding above
the glass transition temperature, the lens edges liquefy, and upon re-solidification, many of the
remaining defects are smoothed out due to surface tension effects of the molten PMMA.
C. 2D planar microlenses
The fabrication route for 2D planar lenses proposed in this article has multiple advantages:
the lenses can be fabricated in the same process stage as the microfluidic features; they are
self-aligned, require a relatively small footprint on a microchip device and can be easily
coupled directly to excitation sources such as LEDs in comparison to optical fibre based wave-
guides which are numerical aperture dependent on their collection and emission. It is worth not-
ing here that the construction of embedded, rigid waveguides, irrespective of the manufacturing
process, have fixed focal points following fabrication and therefore it is critically important to
optimise the planar lenses to match the bespoke application.
FIG. 1. Photographs of the manufactured 2D lenses and their surface profiles (a) post laser ablation, (b) after polishing and
(c) a side by side comparison of the two lens surfaces.
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The optical characteristics of various 2D single and compound lens configurations were
examined here using optical ray-tracing modelling. The most promising of these designs was
subsequently fabricated and its capability experimentally validated through direct fluorescence
excitation and detection tests, as described in Sec. II E. All optical simulations, performed in
OptiCAD 7.0 (OptiCAD Corporation, USA), modelling the focusing of light from a single LED
source onto a virtual excitation area of 0.5mm2 of a microchannel placed within a block of
PMMA. This target area directly corresponds to an excitation of a 1mm long, 500lm deep
channel. In all simulations, a refractive index for PMMA of 1.49 was used.
This work only investigated the potential of a single or up to 4 multiple planoconvex or
planar concave 2D lens configurations, using selected lens radii of greater than or equal to
2 mm, a geometry that could readily be manufactured by the processes described in this study.
Based on the design constraints, the qualitative results from various ray path simulations
yielded a set of physical geometries by which both the biconvex and twin biconvex configura-
tions could be implemented and experimentally investigated. Figure 2 shows a direct compari-
son of ray path simulations for three configurations labelled a to c and the lens parameters of
the two final configurations (b,c) are summarised in Table I.
D. Fluorescence detection
The two most promising configurations (Figures 2(b) and 2(c)) were fabricated using the
CO2 laser ablation system. Each configuration was characterised by the detection sensitivity for
serial dilutions of fluorescein isothiocyanate (FITC) dye and compared against the no-lens con-
figuration. FITC has excitation and emission wavelengths at kex¼ 494 nm and kem¼ 518 nm,
respectively, and was made fresh in a stock solution combined on the first instance with
ethanol, following the manufacturer’s recommendations, and then subsequently diluted with
deionised water. This was required as ethanol degrades PMMA and so dilution in water ensured
the integrity of the microfluidic channels.
The fluorescence measurements were performed using a custom-made fluorescence detection
rig as shown in Figure 3. The LED excitation source comprised a Nichia ultra bright blue LED
(NSPB300A, RS Components, Glasgow, UK) and a band pass excitation filter (FB490-10,
Thorlabs, UK) with kTrans¼ 4906 5 nm (approximately 48% transmission). The detection appara-
tus comprised a 10 x microscope objective (Thorlabs, UK), a FITC optimised band pass emission
filter (HQ535-50m, Chroma, USA), kTrans¼ 5356 25 nm (approximately 75–80% transmission),
and a H9858 photosensor module (Hamamatsu, UK). All components were housed within a
bespoke black PMMA encasing to preserve the alignment of the components relative to each
other, while additionally reducing the background light that could be measured by the photodetec-
tor. The Microscope objective was placed directly above the microfluidic chip at a distance of
approximately 500lm from the surface of the antibody modified biosensing area, as seen in
Figure 3. Such close proximity of the detection optics maximises the collection efficiency, provid-
ing a near 2p coverage of the sensing area. Such a methodology is therefore preferable in com-
parison to light collection only within the chip plane, or using fibre like waveguides where
ultimately a significantly smaller collection angle would be likely.12 Measurements were taken
with the excitation LED placed at approximately 2–3mm distance from the microlens and the de-
tector unit was placed orthogonal to the chip plane, as seen in Figure 3(b). This setup was pre-
ferred as the excitation light from the LED was found to be restricted within the plane of the
microfluidic chip.9 Placing the detection apparatus orthogonal to the microfluidic system reduces
therefore the possibility of the excitation light rays paths terminating on the detector active area
and potentially improves the detection sensitivity of the system.
E. Fluoro-immunoassay reagents and procedure
The fluoro-immunoassay performed in this experiment was carried out using a sandwich style
immunoassay configuration, whereby the antibody is immobilised on the surface of the microflui-
dic chip. The target antigen is bound to the antibody and a secondary labelled antibody binds to
a remaining free epitope of the captured cTnI during the reaction phases. This configuration
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results in the captured antigen being effectively “sandwiched” between the two reaction antibod-
ies. The end point reaction is determined by the detected fluorescence from the secondary labelled
antibodies, which relate directly to the concentration of captured antigens.
Reaction reagents comprised monoclonal anti-cardiac cTnI capture antibodies (19C7),
FITC conjugated monoclonal anti-cardiac cTnI detection antibodies (16A11) and human cTnI
biomarkers, all of which were purchased from Hytest Ltd (Turku, Finland). PBS solution of pH
7.4 was used as the washing buffer (Sigma, UK). Serial dilutions of the cTnI antigen samples
FIG. 2. Optical path simulation results, illustrating the emission from a single LED light source and the propagation of the
resulting light ray as they pass through (a) a blank sheet of PMMA, (b) a single biconvex microlens and (c) a 2 biconvex
microlens configuration. In all simulations light is focused onto an area of 0.5mm2, which represents the excitation area
within a microfluidic channel/chamber. (d) A diagram of a generic example illustrating the various lens parameters, where
R1 is the radius of the lens surface closest to the light source, R2 is the radius of the lens surface farthest from the light
source, W represents the lens width in the chip plane and H represents the lens height in the chip plane.
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were prepared by the dilution of a stock solution with PBS buffer, such that samples of concentra-
tions of 100, 50, 25, 5, 1, and 0.1 ng/ml were obtained. The capture antibodies were immobilised
within the microfluidic channel forming the on-chip biosensing area. It has been demonstrated pre-
viously that antibodies can be immobilised passively onto the surface of the PMMA chips by
direct incubation.26 Several techniques exist in the literature by which chemical modifications of
the PMMA surface can lead to improved antibody immobilisation.27,28 Such methodologies
increase however design complexity and therefore a passive immobilisation methodology was
adopted here owing to its simplicity. To functionalise the microfluidic channels, following micro-
chip fabrication, the microchannel was loaded by capillary forces with 50lg/ml solution of the
capture antibodies. The openings of the filled chip was sealed with polyimide electrical tape
TABLE I. Summary of the lens properties.
Lens configuration Microlens type R1 (mm) R2 (mm) W (mm) H (mm)
Approximate
simulated focal length (mm)
Biconvex Planoconvex 01 10 0 10 15
Planoconvex 02 0 4 4 8 7.5
Dual Biconvex Planoconvex 01 10 0 5 10
Planoconvex 02 0 10 5 10
Planoconvex 03 5 0 10 20
Planoconvex 04 0 5 10 20 6
FIG. 3. (a) (i) Photograph and (ii) schematic of the fluorescence detection apparatus used in conjunction with the microflui-
dic and wave-guiding devices. (b) Relative orientation of the excitation and detection apparatus with respect to the micro-
fluidic device.
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containing a mild silicone adhesive (Pro Power PPC225, Farnell, UK) and the chip was incubated
at 4 C overnight. The polyimide tape prevents evaporation of the test solution during incubation
and the silicone adhesive, in addition to being biocompatible, allows for the tape to be removed
without any adhesive residue being left behind on the chip. Following incubation the capture anti-
body solution was removed and the chip washed three times with PBS buffer to remove any
unbound antibodies. The buffer was then removed and the channel loaded with a 1mg/ml solution
of BSA, re-sealed with fresh polyimide tape and incubated at room temperature for 2 h. The BSA
acts to block the microchannel so that during the sandwich immunoassay non specific binding of
the reaction antigen or labelled antibody is minimised and binding to the bound capture antibodies
becomes the most dynamically favoured outcome. Finally, the BSA solution was removed and the
channel flushed three times with PBS buffer to remove any unbound/residual BSA. The channel
was then loaded with PBS until testing.
III. EXPERIMENTAL RESULTS
A. Microlens validation
Figure 4 shows photographs of the laser cut PMMA microlens structures focusing the light
from a blue LED onto a reaction area within the microfluidic channel containing FITC, with
and without the presence of a suitable emission filter. The photographs provide a qualitative
visual confirmation that lensing is indeed occurring.
To test the focusing ability of the fabricated lenses, a complete system was devised, com-
prising a single polymeric chip containing a microfuidic channel and microlenses. Tests were
performed investigating the lower detection limits of serial dilutions of a stock 1 lM FITC
fluorophore solution when loaded into the microfluidic channels of the polymeric device.
Both microlens configurations were examined and compared to a system containing no micro-
lenses. In all tests, the excitation source and microfluidic channel retain the same spatial
orientation. Sample dilutions examined comprised 1000, 200, 20, 2, and 0.2 nM of FITC. For
each tested FITC sample, a new polymeric device was used to eliminate the possibility of
cross contamination between samples. The blue LED was coupled to the outer most microlens
and the detection rig mounted orthogonal to the detection zone of the fluidic channel. Results
of these tests can be seen in Figure 4(b), which shows a graph of the detected FITC intensity
when interrogating each of the sample dilutions with the three optical configurations. It is
found that the use of the planar lenses increased the detection sensitivity, potentially allowing
for detection of samples below the examined 0.2 nM threshold. In comparison, a system with
no lenses could not detect samples with a concentration of less than 20 nM. The results also
demonstrate that the bioconvex configuration offers superior detection limits of approximately
2 to 4 times greater detected fluorescence signal than with the dual biconvex configuration.
Based on these results the biconvex configuration was selected for the fluorescence immuno-
assay tests.
Prior to performing on-chip fluoro-immunoassays, the system was optimised to improve the
dynamic range for fluorescence detection of the bound FITC labelled antibodies, post reaction.
This primarily comprised adjustment of the photodetector fluorescence radiant sensitivity (as
configurable on the photomultiplier module) and the driving voltage of the LED (2.1V), such
that the system is optimised for low level fluorescence detection. If this were not accommo-
dated for, the system may not be sensitive enough to detect samples at lower concentrations, or
conversely would reach saturation at higher sample concentrations. The results for the lower
detection limits for FITC detection are illustrated in Figure 4, where the system was found to
have a detection limit of approximately 10fM of FITC, which is comparable to the performance
of larger and more expensive commercial fluorescence readers (e.g., 3fM/well FITC for Gemini
XPS microplate reader, Molecular Devices, US and 1fM/well of FITC for FLx800 Fluorescence
Microplate Reader, BioTek, US). Such detection capabilities make the current system ideal for
performing other low level fluorescence bioassays such as real-time sybr green PCR, fluorescent
lifetime measurements, etc., in a similar fashion to the multi use of a general fluorescent read-
ing devices.
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FIG. 4. (a) Photographs of the fabricated lenses focusing light from an LED excitation source with and without a 525 nm
emission filter for systems containing (i) no lenses and (ii) a biconvex lens. (b) Comparison of the detected fluorescence for
various dilutions of FITC using systems containing no lens, biconvex and dual biconvex lens configurations. (c) Lower
detection limit of the optimised developed system for the detected fluorescence of various samples of FITC contained
within the microfluidic chamber of the polymeric chip using the biconvex lens design.
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B. cTnI fluoro-immunoassay
A typical fluoro-immunoassay was performed by loading the functionalised chip first with
the biomarker containing test solution into the microchannel, sealing with polyimide tape and
incubating at room temperature for 30 min. Fluids are simply dispensed into the loading port of
the device and migrate to the exit port through no external energy input of forced agitation of
the device owing to the use of capillary forces to propel fluids in the microchannel. Samples
are removed from the device by simply pipetting the solution at the exit port, which acts to pro-
pel the fluid out of the microfluidic channel due to the suction force of the pipette. It is also
worth noting that gravitational forces can also be used to remove the test fluid by holding the
chip vertically, with the loading port at a point higher than the exit port, thereby the gravita-
tional forces becoming greater than the surface contact forces of the fluid within the device.
With the chip in this orientation a simple tissue or fibrous membrane, which due to the porous
nature of the materials, acts as a capillary pump drawing out the fluid while capturing the waste
solution from the device. Both methodologies provide great simplicity of use for the microflui-
dic device.
Following the initial incubation of the biomarker, the solution was then removed and the
channel washed three times with PBS buffer to remove any unbound biomarker. The channel was
loaded afterwards with a 100lg/ml solution of the FITC labelled detection antibody, sealed with
fresh polyimide tape and incubated for 30 min at room temperature within a darkened box so as
to prevent degradation of the FITC during incubation. The labelled antibody containing solution
was then removed and the microchannel washed three times with PBS buffer to remove any
unbound antibodies. The sample was then ready for fluorescence detection measurements.
The test procedure was performed with independently fabricated devices for all the afore-
mentioned concentrations of cTnI and also for a sample of PBS buffer containing no cTnI,
which acted as a control sample. Results for the detected fluorescence for the examined samples
can be seen in Figure 5, where the raw fluorescence data against concentration is illustrated.
The fluorescence detected at each concentration was measured from three independent samples
and the presented results represent the average fluorescence. From the measurements, a reasona-
ble fit could be made of the data points to construct a calibration curve of the immune-
detection system as seen in Figure 5(a). The system exhibits a near linear response for detected
concentration below 50 ng/ml and the dynamic range of the system is approximately
0–100 ng/ml of cTnI. The lowest concentration measured by the system was 0.1 ng/ml, which is
within the threshold of clinically applicable concentration detection limits. Following standard
methodologies to determine the lower limit of detection, measurements were recording of 15
blank samples, the average was determined, and the corresponding concentration determined of
the average þ 3 standard deviations. The system lower limit of detection was found to be
approximately 0.08 ng/ml of cTnI. Although there are several alternative commercial techniques
and research based biosensors capable of detection limits lower than the demonstrated plat-
form,15,29 the clinically relevant cut-off levels required for diagnostic use is in the range of
0.01–0.1 ng/ml of biomarker.15,30,31 Therefore, the detection capabilities of our presented detec-
tion platform, with a lower limit of detection (LLD) of 0.08 ng/ml is within the diagnostics
threshold and highly applicable for clinical use. In contrast, comparing against a typical clini-
cally implemented point of care device such as the Cobas h232 (Roche Diagnostics LTD), our
lower detection limit surpass this benchmark, further reinforcing the point of care (POC) poten-
tial of the current platform.
If such a device was to be implemented at the POC for “real” operational scenarios, it would
be required to operate using more challenging samples, where biomarkers would be contained in
a patient’s blood/serum samples. The work we have presented has focused on the proof of con-
cept of the immuno-detection platform by which capillary systems operate with integrated optical
components, and as such, has currently only been demonstrated using samples in buffer solutions.
It is anticipated that the direct use of blood samples within the device would yield a higher LLD
due to interferences of the constituents within blood. However, such challenges can be readily
overcome by filtration of blood samples using porous membranes32 or by enhancement of the
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biosensing element of the device. Both techniques would be compatible with the presented biomi-
crofluidic platform and will be the focus of future research.
IV. CONCLUSIONS
CO2 laser ablation techniques have been demonstrated to be applicable for the rapid manu-
facture of PMMA based substrates to create both embedded micro optical lenses and novel,
new capillary action microfluidics channels. The use of backend processing and thermal anneal-
ing allows for the surface quality of the fabricated lenses to be improved upon in comparison
to their native form following laser processing. The resulting manufactured device readily
FIG. 5. Results from the endpoint of the fluoro-immunoassay for the detection of cTnI. (a) Calibration curve and (b) log
concentration graphs of the detected fluorescence.
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allows for the focusing of the light from a standard LED light source onto a finite area within
the chip, offering a marked improvement in detection sensitivity (approximately 2 to 4 times)
of FITC samples for both fabricated lens configurations, as compared to a system where no
lens is present We found that the optimised system, comprised of a single biconvex lens,
allowed for a lower FITC detection limit of 10fM, which is comparable to the performance of
larger and more complex commercial instrumentation.
LEDs offer interesting alternative optical excitation sources as they are cheap, low power
consuming, readily available over a large range of wavelengths, allow for direct excitation of
all prominent fluorophores/quantum dots/fluorescent proteins and can be readily integrated into
miniaturised platforms. The manufactured device, in conjunction with a rudimentary and porta-
ble fluorescence detection rig, was demonstrated to perform fluorescence based immunoassays
with a high degree of sensitivity. The current system has been optimised for the use of FITC
excitation and detection, but could readily be adapted for the use of alternative fluorophores or
fluorescing substances (quantum dots, fluorescent proteins, etc) by adjustment of the LED
source and the excitation and emission filters. Furthermore, the PMMA microchannel device
platform can be readily applied to alternative biological assay formats, such as real-time PCR
and liquid phase bioluminescent based assays, due to its excellent material properties and
biocompatibility.
With the proposed platform, we have demonstrated a low cost and power detection system
of a prominent cardiac biomarker, cTnI, using standard fluoro-immunoassay technology. To
achieve this we have successfully brought together several complimentary technological fea-
tures within the presented biomicrofluic device, which include capillary flow based microflui-
dics, on-chip optical components and embedded biosensing elements. The device has been
designed to operate complimentary to a bespoke fluorescence excitation and detection rig to
create a complete and portable system which addresses the address challenges of transferral of
microfluidic/lab-on-a-chip technology out of the laboratory and into the realms of real work
operational use. Despite the simplicity of the current platform, the device is capable of cTnI
detection at clinically acceptable concentrations, with a lower detection limit of 0.08 ng/ml. We
therefore believe that the microfabricated chip device and the fluorescence detection rig devised
in this work offers considerable potential for use within a clinical environment as POC instru-
mentation and for alternative portable diagnostics based uses, such as within environmental
sampling, on-site hazardous chemical detection, etc.
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